Show simple item record

dc.contributor.authorRubio, G.
dc.contributor.authorLópez-Muñoz, F.
dc.contributor.authorFerre, F.
dc.contributor.authorMartínez-Grass, I.
dc.contributor.authorPonce, G.
dc.contributor.authorPascual, J.M.
dc.contributor.authorJiménez-Arriero, M.A.
dc.contributor.authorÁlamo González, C
dc.date.accessioned2018-06-06T11:44:17Z
dc.date.available2018-06-06T11:44:17Z
dc.date.issued2010-09
dc.identifier.issn0362-5664
dc.identifier.urihttp://hdl.handle.net/20.500.12020/722
dc.description.abstractOBJECTIVE: Anticonvulsant drugs have been used in the treatment of alcohol dependence. The purpose of the present study was to evaluate tolerance and safety of zonisamide in a sample of patients presenting alcohol dependence. METHODS: Open-label zonisamide was examined in 22 outpatients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition alcohol dependence. Zonisamide was started at a dose of 50 mg/d and titrated to a maximun dose of 300 mg/d. Subjects received a baseline evaluation including Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition and the Severity of Alcohol Dependence Scale. Alcohol craving and alcohol consumption were assessed at weeks 2, 4, 6, 8, 10, and 12. The concentration of γ-glutamyltransferase was used as an indirect measure of alcohol consumption. RESULTS: Significant improvement was observed in visual analog scale for craving severity scores, weekly drink consumption, and γ-glutamyltransferase. Zonisamide was well tolerated, with only a dropout due to adverse events. CONCLUSIONS: Zonisamide is safe and well tolerated in this sample and associated with improvement in alcohol craving and alcohol consumption. A placebo-controlled study would be of interest.es
dc.language.isoenes
dc.publisherLippincott Williams & Wilkinses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleEffects of zonisamide in the treatment of alcohol dependencees
dc.typearticlees
dc.identifier.doi10.1097/WNF.0b013e3181f0ed9a
dc.issue.number33es
dc.journal.titleClinical Neuropharmacologyes
dc.page.initial250es
dc.page.final253es
dc.rights.accessRightsopenAccesses
dc.subject.areaCiencias Biomédicases
dc.subject.areaPsicologíaes
dc.subject.keywordPsicofarmacologíaes
dc.subject.keywordAlcoholismoes
dc.subject.unesco3209 Farmacologíaes
dc.subject.unesco3209.09 Psicofarmacologíaes
dc.subject.unesco3205.07 Neurologíaes
dc.subject.unesco3205.07 Neurologíaes
dc.subject.unesco6113.01 Alcoholismoes


Files in this item

File/sSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional